Ceftolozane/tazobactam + Meropenem
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Healthcare-Associated Pneumonia
Conditions
Healthcare-Associated Pneumonia, Ventilator-Associated Pneumonia, Lung Diseases
Trial Timeline
Sep 2, 2014 → Jun 6, 2018
NCT ID
NCT02070757About Ceftolozane/tazobactam + Meropenem
Ceftolozane/tazobactam + Meropenem is a phase 3 stage product being developed by Merck for Healthcare-Associated Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT02070757. Target conditions include Healthcare-Associated Pneumonia, Ventilator-Associated Pneumonia, Lung Diseases.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03230838 | Phase 2 | Completed |
| NCT02070757 | Phase 3 | Completed |
Competing Products
2 competing products in Healthcare-Associated Pneumonia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Cefiderocol + Best Available Therapy | Shionogi | Phase 3 | 77 |
| Cefiderocol + Meropenem + Linezolid | Shionogi | Phase 3 | 77 |